Literature DB >> 3636987

Bacteremia in narcotic addicts at the Detroit Medical Center. I. Microbiology, epidemiology, risk factors, and empiric therapy.

L R Crane, D P Levine, M J Zervos, G Cummings.   

Abstract

The changing microbiology of bacteremia among narcotic addicts in Detroit raised concerns about current presumptive antimicrobial therapy. In a one-year study of incidence, microbiology, sites, and risk factors, 180 bacteremic addicts (15% of addict-related admissions) were followed prospectively. Cases of bacteremia were caused by methicillin-sensitive Staphylococcus aureus (33%), methicillin-resistant S. aureus (MRSA, 24%), streptococci (20%), mixed organisms (11%), Pseudomonas aeruginosa (9%), and miscellaneous other single organisms (3%). Endocarditis (41%) and abscess or cellulitis (34%) were usually found. Multivariate analysis of host factors and addiction habits yielded results predictive of bacterial species but not of infection sites. Previous hospitalization, long-term addiction, and nonprescribed antibiotic use were associated with MRSA acquisition (odds ratio, 8.6:1). All addicts with polymicrobial or P. aeruginosa bacteremia abused pentazocine and tripelennamine (P = .05). Many of the addicts with streptococcal bacteremia were women who did not abuse antibiotics (odds ratio, 20.7:1). Physicians inappropriately prescribed empiric antibiotics for 67 of 72 addicts with MRSA, P. aeruginosa, or polymicrobial infection. The results of regression analysis suggest that, guided by the patient's history, the physician can prescribe appropriate empiric antimicrobial therapy for bacteremia in the febrile addict in Detroit.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3636987     DOI: 10.1093/clinids/8.3.364

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  25 in total

Review 1.  Injection drug use and right sided endocarditis.

Authors:  Rob Moss; Brad Munt
Journal:  Heart       Date:  2003-05       Impact factor: 5.994

2.  Gram-negative endocarditis.

Authors:  Milagros P Reyes; Katherine C Reyes
Journal:  Curr Infect Dis Rep       Date:  2008-07       Impact factor: 3.725

3.  Infected femoral pseudoaneurysms from intravenous drug abuse in young adults.

Authors:  Miran Kozelj; Nina Kobilica; Vojko Flis
Journal:  Wien Klin Wochenschr       Date:  2006       Impact factor: 1.704

Review 4.  Medical complications of intravenous drug use.

Authors:  M D Stein
Journal:  J Gen Intern Med       Date:  1990 May-Jun       Impact factor: 5.128

5.  Streptococcus milleri subcutaneous abscesses in drug addicts.

Authors:  F Müller; A von Graevenitz; T Ferber
Journal:  Infection       Date:  1987 May-Jun       Impact factor: 3.553

6.  Both-sided native valve endocarditis in an intravenous drug misuser.

Authors:  Muhammed Oylumlu; Suleyman Ercan; Fuat Basanalan; Vedat Davutoglu
Journal:  BMJ Case Rep       Date:  2013-12-11

7.  Osteoarticular infection in intravenous drug abusers: influence of HIV infection and differences with non drug abusers.

Authors:  S Muñoz-Fernández; M A Maciá; L Pantoja; A Cardenal; J M Peña; E Martín Mola; A Balsa; F J Barbado; J J Vázquez; J Gijón Baños
Journal:  Ann Rheum Dis       Date:  1993-08       Impact factor: 19.103

8.  Marvelous but Morbid: Infective endocarditis due to Serratia marcescens.

Authors:  Varun K Phadke; Jesse T Jacob
Journal:  Infect Dis Clin Pract (Baltim Md)       Date:  2016-05

9.  Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.

Authors:  Y S Kim; Q Liu; L L Chow; H F Chambers; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

10.  In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models.

Authors:  Masakatsu Tsuji; Morio Takema; Hideaki Miwa; Jingoro Shimada; Shogo Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.